These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
58 related articles for article (PubMed ID: 2621325)
1. Potent inhibition of interleukin 1 beta-mediated human melanoma (A375.6) lysis by corticosteroids, staurosporine, and tilorone. Schultz RM; Howbert JJ; Archer RA Immunopharmacol Immunotoxicol; 1989; 11(2-3):489-506. PubMed ID: 2621325 [TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor and IL-1 associated with plasma membranes of activated human monocytes lyse monokine-sensitive but not monokine-resistant tumor cells whereas viable activated monocytes lyse both. Ichinose Y; Bakouche O; Tsao JY; Fidler IJ J Immunol; 1988 Jul; 141(2):512-8. PubMed ID: 3260254 [TBL] [Abstract][Full Text] [Related]
3. The role of protein kinase C in interleukin 1 and tumor necrosis factor alpha induction of fibroblasts to produce and release granulocyte-macrophage colony-stimulating activity. Zucali JR; Morse C; Dinarello CA Exp Hematol; 1990 Sep; 18(8):888-92. PubMed ID: 2167234 [TBL] [Abstract][Full Text] [Related]
4. Human interleukin 1 is a cytocidal factor for several tumor cell lines. Onozaki K; Matsushima K; Aggarwal BB; Oppenheim JJ J Immunol; 1985 Dec; 135(6):3962-8. PubMed ID: 2415593 [TBL] [Abstract][Full Text] [Related]
5. The incubation of human blood monocytes with tumor necrosis factor-alpha leads to lysis of tumor necrosis factor-sensitive but not resistant tumor cells. Nii A; Fidler IJ Lymphokine Res; 1990; 9(2):113-24. PubMed ID: 2338840 [TBL] [Abstract][Full Text] [Related]
6. Activation of two distinct anti-proliferative pathways, apoptosis and p38 MAP kinase-dependent cell cycle arrest, by tumor necrosis factor in human melanoma cell line A375. Hattori T; Hayashi H; Chiba T; Onozaki K Eur Cytokine Netw; 2001; 12(2):244-52. PubMed ID: 11399512 [TBL] [Abstract][Full Text] [Related]
7. A synthetic peptide homologous to the envelope proteins of retroviruses inhibits monocyte-mediated killing by inactivating interleukin 1. Kleinerman ES; Lachman LB; Knowles RD; Snyderman R; Cianciolo GJ J Immunol; 1987 Oct; 139(7):2329-37. PubMed ID: 2821111 [TBL] [Abstract][Full Text] [Related]
8. A role for the interleukin 1 receptor in the synergistic antitumor effects of human interleukin 1 alpha and etoposide against human melanoma cells. Usui N; Mimnaugh EG; Sinha BK Cancer Res; 1991 Feb; 51(3):769-74. PubMed ID: 1824825 [TBL] [Abstract][Full Text] [Related]
9. Natural and recombinant human interleukin 1-beta is cytotoxic for human melanoma cells. Lachman LB; Dinarello CA; Llansa ND; Fidler IJ J Immunol; 1986 Apr; 136(8):3098-102. PubMed ID: 3485680 [TBL] [Abstract][Full Text] [Related]
10. Down-regulation by interleukin 4 of activation of human alveolar macrophages to the tumoricidal state. Nishioka Y; Sone S; Orino E; Nii A; Ogura T Cancer Res; 1991 Oct; 51(20):5526-31. PubMed ID: 1913671 [TBL] [Abstract][Full Text] [Related]
11. Contribution of IL-6 to the antiproliferative effect of IL-1 and tumor necrosis factor on tumor cell lines. Morinaga Y; Suzuki H; Takatsuki F; Akiyama Y; Taniyama T; Matsushima K; Onozaki K J Immunol; 1989 Dec; 143(11):3538-42. PubMed ID: 2584706 [TBL] [Abstract][Full Text] [Related]
12. Effects of various inhibitors of arachidonic acid oxygenation on macrophage superoxide release and tumoricidal activity. Schultz RM; Nanda SK; Altom MG J Immunol; 1985 Sep; 135(3):2040-4. PubMed ID: 2991375 [TBL] [Abstract][Full Text] [Related]
14. Role of ornithine decarboxylase in the regulation of cell growth by IL-1 and tumor necrosis factor. Endo Y; Matsushima K; Onozaki K; Oppenheim JJ J Immunol; 1988 Oct; 141(7):2342-8. PubMed ID: 2971724 [TBL] [Abstract][Full Text] [Related]
15. Nitric oxide/nucleophile complexes inhibit the in vitro proliferation of A375 melanoma cells via nitric oxide release. Maragos CM; Wang JM; Hrabie JA; Oppenheim JJ; Keefer LK Cancer Res; 1993 Feb; 53(3):564-8. PubMed ID: 8425188 [TBL] [Abstract][Full Text] [Related]
16. Stimulation of tumor necrosis factor release from monocytic cells by the A375 human melanoma via granulocyte-macrophage colony-stimulating factor. Sabatini M; Chavez J; Mundy GR; Bonewald LF Cancer Res; 1990 May; 50(9):2673-8. PubMed ID: 2183930 [TBL] [Abstract][Full Text] [Related]
17. Controlling the production of interleukin-1 and tumor necrosis factor in disease. Dinarello CA Nutrition; 1995; 11(5 Suppl):695-7. PubMed ID: 8748255 [TBL] [Abstract][Full Text] [Related]
18. An assay for the detection of interleukin-1 synthesis inhibitors: effects of antirheumatic drugs. Rordorf-Adam C; Lazdins J; Woods-Cook K; Alteri E; Henn R; Geiger T; Feige U; Towbin H; Erard F Drugs Exp Clin Res; 1989; 15(8):355-62. PubMed ID: 2513175 [TBL] [Abstract][Full Text] [Related]
19. Contrasting effects of the protein kinase C inhibitor staurosporine on the interleukin-1 and phorbol ester activation pathways in the EL4-6.1 thymoma cell line. Dornand J; Bouaboula M; d'Angeac AD; Favero J; Shire D; Casellas P J Cell Physiol; 1992 Apr; 151(1):71-80. PubMed ID: 1560050 [TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 enhances the growth of human melanoma cells derived form primary but not from metastatic tumours. García-Vázquez MD; Boyano MD; Cañavate ML; Gardeazabal J; de Galdeano AG; López-Michelena T; Ratón JA; Izu R; Díaz-Ramón JL; Díaz-Pérez JL Eur Cytokine Netw; 2000 Dec; 11(4):654-61. PubMed ID: 11125310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]